European tech funding hits $35.4 billion while 18% fewer startups secure deals

Europe tech funding sees bigger deals, fewer winners

European tech investment hit $35.4 billion in the first half of 2026, yet fewer startups actually received funding. That paradox defines the current moment across the continent’s startup ecosystem, according to Tracxn’s latest report.

The $35.4 billion total marks a 46% increase from the $24.4 billion raised during the same stretch in 2025. Meanwhile, deal volume dropped sharply. Just 1,555 funding rounds closed in H1 2026, an 18% decline from the 1,904 recorded a year prior. Investors concentrated their capital into fewer, larger bets.

Seven mega-rounds dominated the period, compared to only two in the second half of 2025 and a single one in the first half of that year. Three transactions alone accounted for $5.7 billion, roughly 16% of all European tech funding. Isomorphic Labs raised $2.1 billion in a Series B. Nscale secured $2 billion in Series C financing. Stegra pulled in $1.6 billion at Series A.

The AI infrastructure boom explains much of this shift. Enterprise Applications attracted $17.7 billion, up 69% year over year. Enterprise Infrastructure, which includes data centres and high-performance computing, surged 258% to $4.8 billion. HPC-as-a-service, computational drug discovery, and industrial robotics drew the heaviest investment.

Seed funding showed surprising strength, climbing 84% to $4.6 billion. Early-stage deals rose 19% to $15.6 billion, while late-stage jumped 73% to $15.2 billion. But the pattern held even here: fewer companies received larger checks.

Exits tightened considerably. Acquisitions dropped 25% to 559, the lowest figure in the three halves tracked. CPP Investments and Equinix led with a $4 billion purchase of atNorth. Gilead acquired Tubulis Technologies for $3.1 billion, and Schneider Electric bought Cognite for the same amount.

Public listings fared worse. Eight European tech companies completed IPOs in H1 2026, down 43% from 14 a year earlier and 56% from the prior half. AgomAb Therapeutics, Hemab, and General Oceans were among the few that reached public markets.

London strengthened its grip, capturing 38% of all European tech funding at $13.4 billion, up from 26% six months earlier. Paris slid to 8%, Stockholm held at 8%, and Berlin rounded out the top four with 5%. Together these cities absorbed over half of continental tech investment. The question now: how many companies can survive when capital flows so narrowly?